Page 6 - Annual Report 2020

George Aslanidi, Ph.D.
Molecular Bioengineering and Cancer Vaccine
SECTION LEADER / ASSOCIATE PROFESSOR
“Our lab develops safe and effective gene alteration tools aiming to alter what nature has planned in an effort to change the outcome to a more positive one for patients with rare genetic diseases and
cancer.”
George Aslanidi
Hisae Yoshitomi Karen King Karina Krotova Colin Caine
We use rational molecular bioengineering B, lack a coagulation factor in the blood which
to develop the capsid- and expression
cassette modified adeno-associated virus (AAV) vectors. These optimized viral vectors are further used for possible treatment of a vast variety of rare genetic disorders and cancer. In some cases, genetic materials delivered by virus directly to the diseased tissues and substitute dys- functional gene, such as Factor IX for Homephilia
causes spontaneous bleeding and/or inability of the body to stop bleeding as well as is for Cystic Fibrosis a trans-membrane conductance reg- ulator. CF is lack of proper function of lung cell cause accumulation of excessive mucus, bacterial contamination and ultimately lung failure. In other cases, tumor specific antigens carried by these novel AAV vectors are injected into animal model
SUMMARY
^